David P. Nowotnik
Directeur/Membre du Conseil chez TheraTarget, Inc.
Postes actifs de David P. Nowotnik
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
TheraTarget, Inc.
 TheraTarget, Inc. Pharmaceuticals: MajorHealth Technology TheraTarget, Inc. develops innovative polymer therapeutics for the treatment of cancer. It is a biopharmaceutical drug delivery company developing a variety of polymer-drug conjugates utilizing our nanopolymer drug delivery technologies. The company was founded in October 2008 and is headquartered in Salt Lake, UT. | Directeur/Membre du Conseil | - | - |
Historique de carrière de David P. Nowotnik
Anciens postes connus de David P. Nowotnik
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Corporate Officer/Principal | 01/01/1994 | 01/01/1998 |
| ABEONA THERAPEUTICS INC. | Corporate Officer/Principal | 01/11/1998 | - |
Formation de David P. Nowotnik
| University of London | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
| Royaume-Uni | 2 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
| Director/Board Member | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ABEONA THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
TheraTarget, Inc.
TheraTarget, Inc. Pharmaceuticals: MajorHealth Technology TheraTarget, Inc. develops innovative polymer therapeutics for the treatment of cancer. It is a biopharmaceutical drug delivery company developing a variety of polymer-drug conjugates utilizing our nanopolymer drug delivery technologies. The company was founded in October 2008 and is headquartered in Salt Lake, UT. | Health Technology |
- Bourse
- Insiders
- David P. Nowotnik
- Expérience
